AIM insider trading
HealthcareAIM ImmunoTech Inc.: insider trade history from SEC Form 4 filings.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Company website: aimimmuno.com
AIM insider activity at a glance
FilingIQ tracks 120 insider transactions for AIM in filings since Sep 5, 2019. The most recent transaction is dated Sep 17, 2026.
Across the full history, 43 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest AIM Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at AIM
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for AIM?
- FilingIQ tracks 120 Form 4 insider transactions for AIM (AIM ImmunoTech Inc.), covering filings from Sep 5, 2019 onwards. 4 of those are dated within the last 90 days.
- Are AIM insiders net buyers or net sellers?
- Across the full Form 4 history for AIM, 43 transactions (36%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AIM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is AIM in?
- AIM ImmunoTech Inc. (AIM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.94M.
Methodology & sources
Every AIM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.